Last updated July 18, 2026
Key finding
Total GIR AUC0-30 increased by 1224 mg/kg (95% CI 810–1637, p = 0.00001)
This study investigated the pharmacodynamic properties of insulin analogs detemir and glargine in severely obese patients with type 2 diabetes, revealing significant increases in glucose infusion rates.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the pharmacodynamic properties of insulin analogs detemir and glargine in severely obese patients with type 2 diabetes, revealing significant increases in glucose infusion rates.
The findings highlight the effectiveness of insulin detemir and glargine in managing blood sugar levels in severely obese patients with type 2 diabetes. Given the increasing prevalence of obesity and diabetes, these results are crucial for clinicians in tailoring insulin therapy to optimize patient outcomes.
Study focused on a specific population, limiting generalizability. Effectiveness of insulin analogs may vary in different patient demographics. Sample size and duration may not capture long-term effects.
Published in
Publication details and source links for this paper.
Stefan B, Miriam F, Fabian M, et al. Pharmacodynamic properties of insulin analogs detemir and glargine in severely obese patients with type 2 diabetes. PLOS ONE. 2018;13(8):e0202007. doi:10.1371/journal.pone.0202007
Total GIR AUC0-30 increased by 1224 mg/kg (p = 0.00001)
GIR AUC0-24 increased by 1040 mg/kg (p = 0.00001)
GIR max increased by 0.93 mg/kg/min (p = 0.01)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Detemir, Glargine U100 and Glucose Infusion Rate Area Under the Curve from 0 to 24 Hours, Glucose infusion rate area under the curve from 24 to 30 hours, Maximum glucose infusion rate, and 3 more.
This study contributes evidence to
Primary intervention
Detemir
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
6
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Detemir → Glucose Infusion Rate Area Under the Curve from 0 to 24 Hours
Detemir → Glucose Infusion Rate Area Under the Curve from 0 to 24 Hours
Detemir → Glucose infusion rate area under the curve from 24 to 30 hours
Detemir → Glucose infusion rate area under the curve from 24 to 30 hours
Detemir → Maximum glucose infusion rate
Detemir → Maximum glucose infusion rate
Detemir → Time to maximum glucose infusion rate
Detemir → Time to maximum glucose infusion rate
Detemir → Total glucose infusion rate area under the curve from 0 to 30 hours
Detemir → Total glucose infusion rate area under the curve from 0 to 30 hours
Glargine U100 → Glucose infusion rate area under the curve from 24 to 30 hours with glargine
Glargine U100 → Glucose infusion rate area under the curve from 24 to 30 hours with glargine
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Generated from the study's connected evidence using Evidence Intelligence™.
Detemir appears to improve Glucose Infusion Rate Area Under the Curve from 0 to 24 Hours.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose Infusion Rate Area Under the Curve from 0 to 24 Hours
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Detemir appears to improve Glucose infusion rate area under the curve from 24 to 30 hours.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose infusion rate area under the curve from 24 to 30 hours
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Detemir appears to improve Maximum glucose infusion rate.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Maximum glucose infusion rate
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Detemir appears to improve Time to maximum glucose infusion rate.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time to maximum glucose infusion rate
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
